Adult Dengue Platelet Study (ADEPT)

Tan Tock Seng Hospital

Status: Completed

Conditions: Dengue Fever

Treatments: Procedure: Platelet transfusion; Other: Supportive care

Study type: Interventional

Funder types: Other

Identifiers

NCT01030211

TTSH ADEPT

Details and patient eligibility

About

Retrospective data in children with dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), and in adults with dengue fever (DF), suggested a lack of benefit from prophylactic platelet transfusion for severe thrombocytopenia in dengue patients without bleeding. However, in Taiwan and Singapore, platelet transfusion was given to 13-50% of hospitalised dengue patients. This is a prospective randomised study to examine the safety and efficacy of prophylactic platelet transfusion in adults with dengue and severe thrombocytopenia without bleeding.

The hypotheses are:

1. Prophylactic platelet transfusion is safe in hospitalised dengue patients with severe thrombocytopenia.
2. Prophylactic platelet transfusion is effective in preventing bleeding in hospitalised dengue patients with severe thrombocytopenia.

Full description

Patients fulfilling inclusion and exclusion criteria, and giving informed consent, will be randomised to a treatment arm of 4 units of platelets for every day they have a platelet count <20x10^3/uL, or a control arm with supportive care. Patients will be followed up daily till hospital discharge, and again at day 21.

It is assumed that the incidence of bleeding from randomization to Day 7 or discharge, whichever earlier, is 10% for the control (no transfusion) group and 5% for the intervention (transfusion) group. With 1:1 allocation ratio, to attain 80% power and one-sided 5% type I error rate, the required number of subjects in each arm is 382 by a Chi-square test with Yates' continuity correction. If a drop-out rate of 5% is allowed, the required number increases to approximately 400 per arm.

Enrollment: 372 patients

Sex: All

Ages: 21+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

1. Age ≥ 21years

2. Probable or confirmed dengue

   a) Confirmed dengue: laboratory confirmation of acute dengue by either i) positive polymerase chain reaction (PCR) for viral ribonucleic acid (RNA), or ii)positive NS1 antigen test with a compatible clinical syndrome b) Probable dengue: Positive acute dengue serology and clinical presentation fulfilling either WHO 1997 or 2009 criteria for probable dengue.

   i) 1997 criteria: Acute febrile illness and two or more of the following:

   • headache,
   • retro-orbital pain,
   • myalgia,
   • arthralgia,
   • rash,
   • hemorrhagic manifestations,
   • leucopoenia ii) 2009 criteria: Fever and two of the following:
   • nausea/vomiting,
   • rash,
   • aches/pains,
   • positive tourniquet test,
   • leucopoenia,
   • one or more warning sign
   • abdominal pain/tenderness,
   • persistent vomiting,
   • clinical fluid accumulation,
   • mucosal bleed,
   • lethargy/restlessness,
   • liver enlargement >2cm,
   • increase in haematocrit concurrent with rapid decrease in platelet count

3. Platelets ≤ 20x103/μL

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

372 participants in 2 patient groups

Platelet transfusion

Active Comparator group

Description:

4 units of platelets for patients with platelet count <20x10^3/uL

Treatment:

Procedure: Platelet transfusion

Supportive care

Other group

Description:

No platelet transfusion for patients with platelet count <20x10^3/uL

Treatment:

Other: Supportive care